Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA9/28 16:00TDnetPDF(59KB)
Supplementary Materials Consolidated Financial Statements for the six months ended June 30, 2026 (IFRS)7/24 16:00TDnetPDF(641KB)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)7/24 16:00TDnetPDF(871KB)
Determination of Details Regarding Share Acquisition Associated with the Introduction of the Trust-Based Stock Compensation System4/24 17:00TDnetPDF(135KB)
Supplementary Materials Consolidated Financial Statements for the three months ended March 31, 2026 (IFRS)4/24 17:00TDnetPDF(523KB)
CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the three months ended March 31, 2026)4/24 17:00TDnetPDF(864KB)
Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy and Facioscapulohumeral Muscular Dystrophy3/23 8:30TDnetPDF(65KB)
Other Items Provided Electronically for the Notice of Convocation of the 115th Annual General Meeting of Shareholders2/25 8:00TDnetPDF(434KB)